Safe in Pregnancy | Safe in Children – Up-to-date evidence-based information on vaccines in pregnancy and children

Up-to-date evidence-based information on emerging vaccines in pregnancy and childhood

A regularly updated, comprehensive database and synthesis of published literature related to COVID-19 vaccines in pregnancy through a living systematic review and meta-analyses.

COVID-19 Vaccine Dashboard

PROSPERO Protocol

Pregnant persons

Pairwise Meta Analyses

Quality Assessment

Proportional Meta Analyses

PRISMA Flow Diagram

Summary of Findings

Summary Tables

Supported by the Bill & Melinda Gates Foundation (INV-008443)

Why is this relevant?

600+ million infections and over 6.5 million deaths have been recorded globally, with significant regional variations in infection and case fatality rates.

Pregnant individuals face a 2–3× higher risk of severe illness and preterm birth, while children, despite generally milder symptoms, can, despite being rare, develop Multisystem Inflammatory Syndrome (MISC).

Widely deployed mRNA and vector vaccines have markedly reduced severe outcomes, though booster campaigns remain crucial.

A continuously updated, thorough compilation and analysis of published and unpublished literature concerning Chikungunya vaccines during pregnancy and childhood through a living systematic review and meta-analyses.

Chikungunya Vaccine Dashboard

PROSPERO Protocols

Pregnant persons Children and adolescents

Pairwise and Proportional Meta Analyses

PRISMA Flow Diagram

Summary of Findings

Quality Assessment

Supported by the Safety Platform for Emergency vACcines (SPEAC), Task Force for Global Health, Inc. – The Coalition for Epidemic Preparedness Innovations (CEPI).

Why is this relevant?

Outbreaks have affected millions worldwide, with 70–80% of cases reporting debilitating joint pain and potential long-term arthritic symptoms.

Maternal infections may lead to preterm labor and neonatal complications, while children can experience prolonged recovery periods, impacting daily life.

Transmitted primarily by Aedes mosquitoes, the potential for chikungunya epidemics is high in tropical and subtropical regions.

A vaccine can help prevent infection and reduce the burden of this debilitating disease.

An ongoing, comprehensive review and analysis of published literature on safety, efficacy, effectiveness and immunogenicity of Mpox vaccines during pregnancy and childhood, utilizing a living systematic review and meta-analysis approach.

Mpox Vaccine Dashboard

PROSPERO Protocols

Pregnant persons Children and adolescents

Pairwise and Proportional Meta Analyses

PRISMA Flow Diagram

Summary of Findings

Quality Assessment

Supported by the Safety Platform for Emergency vACcines (SPEAC), Task Force for Global Health, Inc. – The Coalition for Epidemic Preparedness Innovations (CEPI).

Why is this relevant?

The ongoing outbreak of mpox in Africa has caused 100,000 cases, with a case fatality rate ranging from 2.8% to 4.9% in the Democratic Republic of Congo, but lower rates in other countries.

Pregnant individuals are at an increased risk for miscarriage and fetal complications, and pediatric cases may be more severe due to an immature immune response.

Transmission occurs via close contact with infected lesions, body fluids, and respiratory droplets, complicating outbreak control.

Available vaccines offer protection, and new MPOX-specific vaccines are under development.

Several countries are currently experiencing community transmission of Mpox. WHO – list of affected countries. https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--53---29-may-2025

An ongoing, comprehensive collection and examination of published and unpublished literature on Chikungunya vaccines during pregnancy and childhood, with regular updates through a living systematic review and meta-analyses.

Lassa Fever Vaccine Dashboard

PROSPERO Protocols

Pregnant persons Children and adolescents

Pairwise and Proportional Meta Analyses

PRISMA Flow Diagram

Summary of Findings

Quality Assessment

Supported by the Safety Platform for Emergency vACcines (SPEAC), Task Force for Global Health, Inc. – The Coalition for Epidemic Preparedness Innovations (CEPI).

Why is this relevant?

Lassa fever causes 100,000–300,000 infections and approximately 5,000 deaths annually in West Africa, with a 15% case fatality rate among hospitalized patients.

Pregnant individuals face an over 80% maternal and fetal mortality rate in late pregnancy, while children and adolescents suffer higher rates of severe disease.

It spreads primarily through Mastomys natalensis rats excreta, and global travel increases the risk of cases being exported beyond endemic regions.

About 20% of Lassa fever cases progress to severe conditions, such as hemorrhagic fever and multi-organ failure.

Currently, there is no approved vaccine, but promising vaccine candidates are in development.

Disease X is the name given by scientists to an unknown pathogen that could emerge in future and cause a serious international epidemic or pandemic. Disease X is included in the WHO’s updated Blueprint list of diseases for which investing in research and development should be an international
priority. It is also a priority for CEPI’s research and development investments.

Our living systematic review will provide up-to-date information on platforms and components
of vaccines used in pregnancy and childhood which could potentially be adapted to develop
new vaccines against Disease X. We will also be ready to rapidly deploy a living systematic
review of future vaccines against Disease X to protect pregnant people and children.

Why is this relevant?

Represents a serious international epidemic that could be caused by a pathogen currently unknown to cause human disease.

There are ongoing efforts aimed at developing platform vaccines and broad‐spectrum antivirals to mitigate severe outcomes once an outbreak emerges.

Vulnerable groups, including pregnant individuals and children, may experience disproportionately high rates of maternal and pediatric complications, underscoring the urgency for proactive research and preparedness.

Get In Touch with Us

Andrea Meyer

Director of Global Health Research

Up-to-date evidence-based information on emerging vaccines in pregnancy and childhood

Why is this relevant?

Why is this relevant?

Why is this relevant?

Why is this relevant?

Why is this relevant?

Get In Touch with Us

Andrea Meyer

Quick Links

Contact Us

Andrea Meyer